These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15960287)

  • 21. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
    Abutaily AS; Addis BJ; Roche WR
    J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas.
    Osborn M; Pelling N; Walker MM; Fisher C; Nicholson AG
    Histopathology; 2002 Oct; 41(4):301-7. PubMed ID: 12383211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.
    King JE; Thatcher N; Pickering CA; Hasleton PS
    Histopathology; 2006 Feb; 48(3):223-32. PubMed ID: 16430468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study.
    Ordóñez NG
    Mod Pathol; 2006 Mar; 19(3):417-28. PubMed ID: 16415794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
    Ordóñez NG
    Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cytokeratin- and calretinin-negative staining sarcomatoid malignant mesothelioma.
    Hurtuk MG; Carbone M
    Anticancer Res; 2004; 24(5B):3097-102. PubMed ID: 15510595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TLE1 expression in malignant mesothelioma.
    Matsuyama A; Hisaoka M; Iwasaki M; Iwashita M; Hisanaga S; Hashimoto H
    Virchows Arch; 2010 Nov; 457(5):577-83. PubMed ID: 20857142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation.
    Hinterberger M; Reineke T; Storz M; Weder W; Vogt P; Moch H
    Mod Pathol; 2007 Feb; 20(2):248-55. PubMed ID: 17361207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.
    Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG
    Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
    Pan CC; Chen PC; Chou TY; Chiang H
    Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
    Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A
    Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies].
    Chenard-Neu MP; Kabou A; Mechine A; Brolly F; Orion B; Bellocq JP
    Ann Pathol; 1998 Dec; 18(6):460-5. PubMed ID: 10051912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
    Oates J; Edwards C
    Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma.
    Ordóñez NG
    Hum Pathol; 2005 Apr; 36(4):372-80. PubMed ID: 15891998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
    Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
    Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma.
    Attanoos RL; Goddard H; Gibbs AR
    Histopathology; 1996 Sep; 29(3):209-15. PubMed ID: 8884348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Value of claudin-4 immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Am J Clin Pathol; 2013 May; 139(5):611-9. PubMed ID: 23596113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.
    Naso JR; Tsuji S; Churg A
    Am J Surg Pathol; 2020 Aug; 44(8):1143-1148. PubMed ID: 32205484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.